AU2019230883B2 - Pyrrolidineamide derivatives and uses thereof - Google Patents

Pyrrolidineamide derivatives and uses thereof Download PDF

Info

Publication number
AU2019230883B2
AU2019230883B2 AU2019230883A AU2019230883A AU2019230883B2 AU 2019230883 B2 AU2019230883 B2 AU 2019230883B2 AU 2019230883 A AU2019230883 A AU 2019230883A AU 2019230883 A AU2019230883 A AU 2019230883A AU 2019230883 B2 AU2019230883 B2 AU 2019230883B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
alkoxy
och
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019230883A
Other languages
English (en)
Other versions
AU2019230883A1 (en
Inventor
Kangzhi CHEN
Chuanfei JIN
Yingjun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of AU2019230883A1 publication Critical patent/AU2019230883A1/en
Application granted granted Critical
Publication of AU2019230883B2 publication Critical patent/AU2019230883B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2019230883A 2018-03-08 2019-03-07 Pyrrolidineamide derivatives and uses thereof Active AU2019230883B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810192198 2018-03-08
CN201810192198.6 2018-03-08
PCT/CN2019/077249 WO2019170115A1 (en) 2018-03-08 2019-03-07 Pyrrolidineamide derivatives and uses thereof

Publications (2)

Publication Number Publication Date
AU2019230883A1 AU2019230883A1 (en) 2020-09-24
AU2019230883B2 true AU2019230883B2 (en) 2024-02-01

Family

ID=67845842

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019230883A Active AU2019230883B2 (en) 2018-03-08 2019-03-07 Pyrrolidineamide derivatives and uses thereof

Country Status (8)

Country Link
US (1) US11225460B2 (https=)
EP (1) EP3762364B1 (https=)
JP (1) JP7405756B2 (https=)
CN (1) CN110240557B (https=)
AU (1) AU2019230883B2 (https=)
CA (1) CA3092747A1 (https=)
SG (1) SG11202008543RA (https=)
WO (1) WO2019170115A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240317681A1 (en) * 2020-07-07 2024-09-26 Sunshine Lake Pharma Co., Ltd. Pyrrolidine amide derivative salt and use thereof
CN113896671B (zh) * 2020-07-07 2023-06-09 广东东阳光药业有限公司 吡咯烷酰胺衍生物的盐及其用途
CN113896670B (zh) * 2020-07-07 2023-06-09 广东东阳光药业有限公司 吡咯烷酰胺衍生物的盐及其用途
CN114573491B (zh) * 2020-12-01 2023-12-08 广东东阳光药业股份有限公司 吡咯烷酰胺衍生物的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040108A1 (en) * 2003-10-15 2005-05-06 Newron Pharmaceuticals S.P.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective mao-b inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
WO2000033788A2 (en) 1998-12-11 2000-06-15 American Biogenetic Sciences Inc. Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
FR2799461B1 (fr) 1999-10-11 2002-01-04 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
WO2006013049A2 (en) * 2004-08-02 2006-02-09 F.Hoffmann-La Roche Ag Benzyloxy derivatives as maob inhibitors
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
US20070078172A1 (en) 2005-06-16 2007-04-05 Jenrin Discovery Mao-b inhibitors useful for treating obesity
BRPI0821026A2 (pt) 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
CA2886904A1 (en) * 2012-10-02 2014-04-10 Cyril Montagne Pyrrolidines
EP3601255A1 (en) 2017-03-21 2020-02-05 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040108A1 (en) * 2003-10-15 2005-05-06 Newron Pharmaceuticals S.P.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective mao-b inhibitors

Also Published As

Publication number Publication date
CN110240557A (zh) 2019-09-17
WO2019170115A1 (en) 2019-09-12
CN110240557B (zh) 2023-05-09
AU2019230883A1 (en) 2020-09-24
EP3762364A1 (en) 2021-01-13
JP7405756B2 (ja) 2023-12-26
US20210053918A1 (en) 2021-02-25
JP2021515019A (ja) 2021-06-17
EP3762364B1 (en) 2023-08-23
SG11202008543RA (en) 2020-10-29
US11225460B2 (en) 2022-01-18
CA3092747A1 (en) 2019-09-12
EP3762364A4 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
US11858910B2 (en) Pyridinylmethylenepiperidine derivatives and uses thereof
US11285153B2 (en) Substituted pyrimidine piperazine compound and use thereof
AU2019230883B2 (en) Pyrrolidineamide derivatives and uses thereof
WO2020216152A1 (en) 8-substituted aryl vinyl xanthine derivatives and uses thereof
CN112300165B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN110981876B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN112010818B (zh) 吗啉酰胺衍生物及其用途
CN111072604B (zh) α-氨基酰胺衍生物及其用途
CN108912029B (zh) 含氮杂环酰胺衍生物及其用途
HK40036563A (en) Pyrrolidineamide derivatives and uses thereof
HK40036563B (en) Pyrrolidineamide derivatives and uses thereof
CN111018856B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN109734712B (zh) 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
CN111072676A (zh) 含氮稠合三环衍生物及其用途
CN110938064B (zh) N-取代哌啶酰胺衍生物及其用途
CN118063445A (zh) 吡咯烷酰胺衍生物及其用途
CN118063444A (zh) 氮杂环丁烷酰胺衍生物及其用途
CN111072663A (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
HK40027192A (en) Substituted pyrimidine piperazine compound and use thereof
HK40027192B (en) Substituted pyrimidine piperazine compound and use thereof
CN108864033A (zh) 苯基取代的酰肼衍生物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)